Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • JULY 2021 Issue has been successfully launched on 1 July 2021.



Niyati Talwar and Shaffi Khurana Tangri


Nose-to-brain conveyance addresses a major context in Novel drug delivery systems. There are an enormous number of neurological illnesses that require treatments in which the medication should reach the cerebrum and cranial cavity keeping away the obstruction because of the blood-brain barrier (BBB) and the issues associated with the fundamental organization for example, drug bioavailability and toxicity. Consequently, the improvement of nasal delivery ready to convey the medication into the cranial cavity is of expanding significance. The blood-brain barrier (BBB) is frequently a restricting variable for drugs arriving at the cerebrum. Bypassing the BBB intranasally (IN), or additionally called the nose to the brain, is an intriguing and oftentimes explored idea for conveying medications to the brain. The goal was to study the attainability and estimation of a normalized IN assessment of direct brain conveyance. The IN course contrasted with the parenteral course to choose if there is a potential direct cerebrum transport. The study showed that the focuses and extents in blood and tissue are exceptional factors and not generally reproducible. The blood-brain barrier and the blood-cerebrospinal fluid barrier are significant barriers to drug delivery in the central nervous system (CNS)since they prevent most molecules from accessing the brain. Alternative drug delivery methods, such as intraparenchymal or intrathecal, are invasive and bear the risk of infection. Nose-to-brain delivery, on the other hand, is a minimally invasive drug delivery method. The drug is delivered from the nasal cavity to the brain through an administration pathway that bypasses the blood-brain barrier. The CNS is especially close to the skull base, which is situated at the roof of the nasal cavity. The olfactory mucosa covers this region. The architecture, structure, and physicochemical characteristics of nose-to-brain drug delivery formulations are used to design and customize them. The mucosa is a crucial criterion. As a result, we'll go through the most up-to-date information on the properties of the nasal and, in particular, the olfactory mucosa, which will help us design rational intranasal formulations and dosage types. In addition, the data may be used to improve systemic or local intranasal drug delivery systems, as well.

Keywords: Olfactory Pathway, Trigeminal Pathway, Blood-Brain Barrier, Alzheimer's Disease, Parkinson?s Disease, Migraine, Neurotherapeutic Delivery.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More